A bipartisan bill proposed on June 2 by U.S. Rep. John Moolenaar (R-MI) is designed to protect research, innovation, and the medicines Americans depend on.
The Biotech Investment National Security (BINSA) Act of 2026, H.R. 9102, which Rep. Moolenaar sponsored alongside bill cosponsor U.S. Rep. Debbie Dingell (D-MI), would amend the Comprehensive Outbound Investment National Security (COINS) Act of 2025 to add biotechnology — specifically pharmaceutical and biological product development — to the list of sectors subject to outbound investment screening.
“Right now, American companies including Pfizer and Bristol Myers Squibb are making dangerous deals with Chinese biotech companies that threaten the future of American pharmaceutical production,” said Rep. Moolenaar, chairman of the Select Committee on China. “We must not allow American investment, expertise, and technology to offshore our biotech industry, hand Chinese companies another chokehold over our economy, and hollow out our nation’s research infrastructure.”
Additionally, H.R. 9102 would make U.S. pharmaceutical licensing deals, joint ventures, and equity investments with Chinese-covered foreign persons subject to review by the U.S. Treasury Department, and direct Treasury to issue implementing regulations within one year, according to a bill summary provided by Rep. Moolenaar’s office.
Among other provisions, the bill would require the U.S. Secretary of Defense to assess within 60 days whether U.S. capital flows into Chinese biotechnology negatively affect national security and military readiness.
“We need to pass this legislation and subject drug companies’ deals with China to the same scrutiny we apply to investment in China’s tech sector,” Rep. Moolenaar said. “Otherwise, China will continue taking American innovation, and use it to bankrupt our businesses and industries, while building supply chains in its favor.”
Rep. Dingell added that the bill is important because it will ensure that American investment doesn’t inadvertently support the development or expansion of biotechnology industries that could threaten America’s economic and national security interests.
“The United States must remain the global leader in innovation, and we cannot afford to be dependent on foreign competitors — like the People’s Republic of China — for critical pharmaceutical ingredients, drug development, and medical supply chains,” said the congresswoman. “Strengthening America’s biotechnology and pharmaceutical industries will help protect patients, create jobs, and safeguard our nation’s health and security.”